Skip to content
Screener

Lineage Cell Therapeutics LCTX Q1 2026 earnings

Reported May 12, 2026 · After market close

Revenue$1.7MMiss by $1.9M
EPS-$0.03Miss by $0.01
Revenue estimate$3.6M
EPS estimate-$0.02

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$1.3M
EPS estimate-$0.03

FAQ

When did Lineage Cell Therapeutics report Q1 2026 earnings?
Lineage Cell Therapeutics (LCTX) reported Q1 2026 earnings on May 12, 2026 after market close.
What were Lineage Cell Therapeutics's Q1 2026 revenue and EPS?
Lineage Cell Therapeutics reported revenue of $1.7M and eps of $-0.03 for Q1 2026.
Did Lineage Cell Therapeutics beat estimates in Q1 2026?
Revenue missed the consensus estimate of $3.6M by $1.9M. EPS missed the consensus estimate of $-0.02 by $0.01.
How did Lineage Cell Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 14.8% from $1.5M a year earlier and eps declined 50.0% from $-0.02.
Where can I find Lineage Cell Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-219421) and the 10-Q periodic report (0001193125-26-219479) directly on SEC EDGAR. The filing index links above go to sec.gov.